APVO Aptevo Therapeutics Inc

Price (delayed)

$4.69

Market cap

$2.5M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$62.48

Enterprise value

-$9.01M

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, ...

Highlights
The company's debt fell by 43% YoY and by 3.2% QoQ
APVO's EPS has dropped by 190% year-on-year but it is up by 38% since the previous quarter
APVO's gross profit has dropped by 100% year-on-year
The revenue has dropped by 100% year-on-year

Key stats

What are the main financial stats of APVO
Market
Shares outstanding
533,464
Market cap
$2.5M
Enterprise value
-$9.01M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.15
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$17.41M
EBITDA
-$16.84M
Free cash flow
-$11.73M
Per share
EPS
-$62.48
Free cash flow per share
-$42.19
Book value per share
$30.52
Revenue per share
$0
TBVPS
$89.34
Balance sheet
Total assets
$24.84M
Total liabilities
$12.62M
Debt
$5.4M
Equity
$12.22M
Working capital
$11.84M
Liquidity
Debt to equity
0.44
Current ratio
2.64
Quick ratio
2.34
Net debt/EBITDA
0.68
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-60.1%
Return on equity
-104.8%
Return on invested capital
-237.1%
Return on capital employed
-98.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

APVO stock price

How has the Aptevo Therapeutics stock price performed over time
Intraday
15.52%
1 week
4.69%
1 month
2,912.2%
1 year
148.15%
YTD
2,491.16%
QTD
2,491.16%

Financial performance

How have Aptevo Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$28.88M
Net income
-$17.41M
Gross margin
N/A
Net margin
N/A
APVO's gross profit has dropped by 100% year-on-year
The revenue has dropped by 100% year-on-year
APVO's net income is down by 8% QoQ
The company's operating income rose by 4.3% QoQ

Growth

What is Aptevo Therapeutics's growth rate over time

Valuation

What is Aptevo Therapeutics stock price valuation
P/E
N/A
P/B
0.15
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
APVO's EPS has dropped by 190% year-on-year but it is up by 38% since the previous quarter
APVO's P/B is 97% below its 5-year quarterly average of 5.1 and 70% below its last 4 quarters average of 0.5
Aptevo Therapeutics's equity has decreased by 32% YoY and by 17% QoQ
The revenue has dropped by 100% year-on-year

Efficiency

How efficient is Aptevo Therapeutics business performance
The company's return on invested capital fell by 31% QoQ
The return on equity has declined by 17% since the previous quarter
Aptevo Therapeutics's ROA has decreased by 16% from the previous quarter

Dividends

What is APVO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for APVO.

Financial health

How did Aptevo Therapeutics financials performed over time
APVO's total assets is 97% higher than its total liabilities
APVO's total assets is down by 27% YoY and by 8% QoQ
The total liabilities has contracted by 22% YoY
The company's debt is 56% lower than its equity
The company's debt fell by 43% YoY and by 3.2% QoQ
Aptevo Therapeutics's equity has decreased by 32% YoY and by 17% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.